MAPS in the Media

The New York Times

Obama Administration Set to Remove Barrier to Marijuana Research
by Catherine Saint Louis and Matt Apuzzo on August 10, 2016. The New York Times reports on the U.S. Drug Enforcement Administration (DEA)’s decision to end the federal monopoly on marijuana for research. “It’s clear that this was a significant hurdle in limiting the quantity of clinical research taking place in the U.S.,” said Paul Armentano, the deputy director of the National Organization for the Reform of Marijuana Laws.

DEA Keeps Marijuana on List of Dangerous Drugs, Frustrating Advocates
by Catherine Saint Louis on August 11, 2016. The New York Times reports on the U.S. Drug Enforcement Administration (DEA)’s decision against removing marijuana from the list of Schedule I substances due to a lack of medical research. MAPS Founder Rick Doblin, Ph.D., details how conducting marijuana research can lead to federal approval of medical marijuana, stating, “If you make it through the F.D.A.,” explains Doblin, “insurance companies will cover it.”

“My Therapist Gave Me a Pill”: Can MDMA Help Cure Trauma?
by Olivia Solon September 16, 2016. The Guardian interviews study participants Alice and CJ about how MDMA-assisted psychotherapy helped them overcome chronic, treatment-resistant posttraumatic stress disorder (PTSD). The article covers MAPS’ upcoming Phase 3 clinical trials of MDMA-assisted psychotherapy for PTSD, includes a brief history of the politics surrounding MDMA, and features additional interviews with researchers Ben Sessa, M.D., Michael Mittoefer, M.D., and MAPS Founder Rick Doblin, Ph.D. “The MDMA just pulls things out of you,” says Alice. “It supports you. You can start looking at all your experiences and how they are affecting you.”

The Guardian

MDMA as a Probe and Treatment for Social Behaviors
by Boris D. Heifets, M.D., Ph.D., Robert C. Malenka, M.D., Ph.D. on July 14, 2016. The peer-reviewed scientific journal Cell publishes a new review of current research into the use of MDMA as an adjunct to psychotherapy for a range of neuropsychiatric disorders. The article summarizes current knowledge about MDMA’s mechanism of action, highlighting its ability to catalyze prosocial, empathogenic effects which may help treat symptoms of medical conditions such as major depressive disorder, social anxiety in autistic adults, posttraumatic stress disorder (PTSD), and schizophrenia.

Nature

Why the US Decision to Expand Marijuana Supply for Research Matters
by Ramin Skibba August 12, 2016

Stars and Stripes

Can Marijuana Improve PTSD Symptoms for Veterans?
by Matthew M. Burke September 5, 2016

KQED Science

Can MDMA Help Relieve Social Anxiety Epidemic Among Autistic People?
by April Dembosky October 24, 2016

Rolling Stone

LSD Now: How the Psychedelic Renaissance Changed Acid
by Jesse Jarnow October 6, 2016

Volteface

Legitimising MDMA, ‘The Love Drug’, For Couples Therapy
by Rosalind Stone September 20, 2016

The Verge

Why Banning the Opiate-Like Plant Kratom Might Do More Harm Than Good
by Alessandra Potenza September 22, 2016